Recent Episodes

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

Host Brandon Mancini, MD, MBA, FACRO, discusses presentations from ASCO GU 2026 featuring potential advances in the use of radiotherapeutic regimens.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Experts review potential clinical advances highlighted at the 2026 ASCO Gastrointestinal Cancers Symposium.

Experts discuss how issues related to prostate cancer diagnoses and access to care differ across practices based in the US and India.

Researchers and clinicians share key updates in leukemia, lymphoma, and myelodysplastic syndrome that they presented at the 2026 Tandem Meetings.

Experts outline current initiatives from the American College of Radiation Oncology as well as potential next steps for advancing the field.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

Nathan Goodyear, MD, discussed key insights in integrative oncology care as well as evidence-based, patient-centric tools that may optimize QOL outcomes.

Host Brandon Mancini, MD, MBA, FACRO, introduces a special podcast series focused on delivering key insights and takeaways in the radiation oncology space.

Opening dialogue and establishing connections across different oncology camps may enhance the use of integrative modalities and bolster patient outcomes.

Experts break down the clinical trial data and regulatory developments that made 2025 a “remarkable year” in kidney and bladder cancer management.

Jose G. Trevino II, MD, FACS, emphasized educating patients and physicians alike to help recognize early signs of pancreatic ductal adenocarcinoma.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Experts discussed supportive care and why it should be integrated into standard oncology care.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.